Tumor Extracellular Vesicle–Derived PD-L1 Promotes T Cell Senescence Through Lipid Metabolism Reprogramming

PD-L1 in Tumor-Derived Extracellular Vesicles Promotes T Cell Senescence through Lipid Metabolism Reprogramming Academic Background In recent years, immunotherapy has shown great promise in cancer treatment, particularly in checkpoint blockade therapies targeting PD-1/PD-L1 (programmed cell death protein 1 and its ligand) and CTLA-4 (cytotoxic T-ly...

In Vivo Expansion of Gene-Targeted Hepatocytes through Transient Inhibition of an Essential Gene

Breakthrough in Gene Therapy: Repair Drive Technology Enables In Vivo Expansion of Hepatocytes Academic Background Gene therapy has become a hot topic in medical research in recent years, especially for liver diseases. Due to the central role of the liver in metabolism, it has become a critical target for research. Although existing gene-editing te...

Coactivation of Innate Immune Suppressive Cells Induces Acquired Resistance Against Combined TLR Agonism and PD-1 Blockade

Mechanism of Combined Immune Checkpoint Blockade Therapy Academic Background Immune Checkpoint Blockade (ICB) is a revolutionary cancer treatment aimed at reactivating effector T cells to combat cancer. However, more than half of patients do not respond to ICB, especially those with immunologically “cold” tumors (tumors with fewer immune cells in t...

Organ-Specific Microenvironments Drive Divergent T Cell Evolution in Acute Graft-Versus-Host Disease

Study on Organ-Specific T Cell Differentiation in Acute Graft-Versus-Host Disease (AGVHD) Academic Background Acute Graft-Versus-Host Disease (AGVHD) is a common and severe complication following Allogeneic Hematopoietic Stem Cell Transplantation (HCT), caused by the immune attack of donor T cells on host tissues. Although the pathological mechanis...

Triple Knockdown of CD11a, CD49d, and PSGL1 in T Cells Reduces CAR-T Cell Toxicity but Preserves Activity Against Solid Tumors in Mice

Study on Reducing Toxicity of CAR-T Cell Therapy for Solid Tumors Academic Background Chimeric antigen receptor T-cell (CAR-T) therapy has made significant progress in treating hematologic malignancies, but its application in solid tumors faces major challenges. Solid tumors often lack tumor-specific antigens (TSAs), and CAR-T cells may attack norm...